Tandem Autologous Stem Cell Transplantation Improves Outcomes in Newly Diagnosed Multiple Myeloma with Extramedullary Disease and High-Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation

Clicks: 349
ID: 114940
2019
Free PDF
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
Although high-dose therapy and autologous stem cell transplant combined with novel agents continues to be the hallmark of first-line treatment in newly diagnosed transplant-eligible multiple myeloma patients, the impact of tandem autologous or autologous/reduced-intensity allogeneic transplant for p …
Reference Key
n2019biologytandem Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Gagelmann N;Eikema DJ;Koster L;Caillot D;Pioltelli P;Lleonart JB;Reményi P;Blaise D;Schaap N;Trneny M;Passweg J;Porras RP;Cahn JY;Musso M;Poiré X;Fenk R;Itälä-Remes M;Pavone V;Fouillard L;Maertens J;Bron D;Pouli A;Schroyens W;Schönland S;Garderet L;Yakoub-Agha I;Kröger N;;
Journal biology of blood and marrow transplantation : journal of the american society for blood and marrow transplantation
Year 2019
DOI
DOI not found
URL
https://www.pubmed.gov/31288095/
Keywords
medical National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine adult female male aged middle aged risk factors Clinical Trial Multicenter Study follow-up studies survival rate disease-free survival societies pmid:31288095 doi:10.1016/j.bbmt.2019.07.004 nico gagelmann diderik-jan eikema nicolaus kröger autografts chromosome aberrations* europe / epidemiology multiple myeloma* / genetics multiple myeloma* / mortality multiple myeloma* / therapy stem cell transplantation*

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.